IP Library Granted Patent US 10,076,492
Granted Patent B2
US 10,076,492 · App. 14/992,592 · Granted Sep 18, 2018

Biodegradable intravitreal tyrosine kinase implants

Inventors: Jeffrey L. Edelman (Irvine, CA); Patrick M. Hughes (Aliso Viejo, CA); Thomas C. Malone (Irvine, CA); Gerald W. DeVries (San Clemente, CA); Joan-En Chang-Lin (Tustin, CA); Jane-Guo Shiah (Irvine, CA); Thierry Nivaggioli (Atherton, CA); Lon T. Spada (Walnut, CA); Wendy M. Blanda (Tustin, CA)
Assignee: Allergan, Inc.
A61K9/0051A61F9/0017A61K9/204A61K31/404A61K31/454A61K31/5377A61K47/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,076,492
App. No.
14/992,592
Granted
Sep 18, 2018
Kind
B2
Abstract

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

Claims (4)

1. A method of making a biodegradable intravitreal implant, comprising the step of: extruding a mixture of a tyrosine kinase inhibitor and a biodegradable polymer to form a biodegradable implant that degrades at a rate effective to sustain release of an amount of the tyrosine kinase inhibitor from the implant for at least about one week after the implant is placed in the vitreous of an eye.

2. The method of claim 1 , wherein the mixture consists essentially of the tyrosine kinase inhibitor and the biodegradable polymer.

3. The method of claim 1 , wherein the polymer comprises a polymer selected from the group consisting of poly (lactide-co-glycolides), polycaprolactones, and combinations thereof.

4. The method of claim 1 , wherein the tyrosine kinase inhibitor is provided in an amount from about 30% by weight to about 70% by weight of the implant, and the biodegradable polymer matrix comprises a poly(lactide-co-glycolide) in an amount from about 30% by weight to about 70% by weight of the implant.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2016
From: HUGHES, PATRICK M.; MALONE, THOMAS C.; DEVRIES, GERALD; EDELMAN, JEFFREY L.; CHANG-LIN, JOAN-EN; SHIAH, JANE GUO; SPADA, LON T.; BLANDA, WENDY M.; NIVAGGIOLI, THIERRY
To: ALLERGAN, INC.
Reel/Frame 037455/0188 →
Continuity (3)
Division 11119001 · Apr 29, 2005
Continuation In Part 10837361 · Apr 30, 2004
Related Publication 20160199297A1 · Jul 14, 2016
Cited By (1)
US 12,589,025